Trial Profile
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms SubDueP
- 27 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 27 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 15 Feb 2010 New trial record